Check-Cap, the Israel-based developer of the first non-invasive, prep-free imaging test for colon cancer, received an undisclosed sum from General Electric’s healthcare and venturing divisions, GE Healthcare and GE Capital, on 1st February. The investment was made through GE’s Healthymagination fund. The funding comes less than a year after Check-Cap pulled in NIS 35m ($9.8m) in funding from unnamed investors. In addition to the investment, Check-Cap and GE Healthcare-Israel also signed a development and supply agreement that will see GE provide diagnostic imaging sensors for Check-Cap’s capsule-based treatment. 

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?